Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

142.91 +6.90 (+5.07%)
Delayed Quote Updated: 1:25 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome (AXSM) Q3 2026 Earnings Call Transcript ↗
AUVELITY revenue surged 52% as Alzheimer's disease agitation gains traction. 
Via The Motley Fool
Topics Earnings
News headline image
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call ↗
Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer’s... 
Via MarketBeat
Topics Earnings
Axsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings: In-Line Revenue, Narrower Loss, but Shares Slide ↗
Via Chartmill
News headline image
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035? ↗
The stock has experienced a pullback in the past few months. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility ↗
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size. 
Via The Motley Fool
News headline image
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) ↗
These drugmakers are capitalizing on their pipeline successes. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Under-the-Radar Stocks to Buy and Hold ↗
They aren’t the best-known corporations in the biotech industry, but they can deliver excellent long-term returns. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? ↗
Auvelity's Alzheimer's expansion could transform Axsome by 2030. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? ↗
Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential. 
Via The Motley Fool
News headline image
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in... 
Via MarketBeat
News headline image
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference ↗
Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual... 
Via MarketBeat
News headline image
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? ↗
Or are its best days in the rearview mirror? 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases... 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗
Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence. 
Via The Motley Fool
News headline image
Is Axsome Therapeutics a Buy on the Dip? ↗
The stock slipped about 15% over the past three months. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable. 
Via The Motley Fool
News headline image
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗
The company has also crushed broader equities over the past five years. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a... 
Via Benzinga
News headline image
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a... 
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.